2021 Ranking

Competition is close for top positions

Pharmaceutical companies continue to inch forward in addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.

1 GlaxoSmithKline plc
0 1 2 3 4 5
4.23

GlaxoSmithKline plc

Read more
2 Novartis AG
0 1 2 3 4 5
4.18

Novartis AG

Read more
3 Johnson & Johnson
0 1 2 3 4 5
3.76

Johnson & Johnson

Read more
4 Pfizer Inc.
0 1 2 3 4 5
3.65

Pfizer Inc.

Read more
5 Sanofi
0 1 2 3 4 5
3.47

Sanofi

Read more
6 Takeda Pharmaceutical Co. Ltd.
0 1 2 3 4 5
3.31

Takeda Pharmaceutical Co. Ltd.

Read more
7 AstraZeneca plc
0 1 2 3 4 5
3.30

AstraZeneca plc

Read more
8 Merck KGaA (Merck)
0 1 2 3 4 5
3.09

Merck KGaA (Merck)

Read more
9 Roche Holding AG
0 1 2 3 4 5
3.07

Roche Holding AG

Read more
10 Novo Nordisk A/S
0 1 2 3 4 5
2.96

Novo Nordisk A/S

Read more
11 Eisai Co. Ltd.
0 1 2 3 4 5
2.87

Eisai Co. Ltd.

Read more
12 Boehringer Ingelheim GmbH
0 1 2 3 4 5
2.84

Boehringer Ingelheim GmbH

Read more
13 Bayer AG
0 1 2 3 4 5
2.63

Bayer AG

Read more
14 Astellas Pharma Inc.
0 1 2 3 4 5
2.33

Astellas Pharma Inc.

Read more
14 Gilead Sciences Inc.
0 1 2 3 4 5
2.33

Gilead Sciences Inc.

Read more
15 Merck & Co., Inc. (MSD)
0 1 2 3 4 5
1.88

Merck & Co., Inc. (MSD)

Read more
16 Daiichi Sankyo Co. Ltd.
0 1 2 3 4 5
1.80

Daiichi Sankyo Co. Ltd.

Read more
17 AbbVie Inc.
0 1 2 3 4 5
1.73

AbbVie Inc.

Read more
18 Eli Lilly & Co.
0 1 2 3 4 5
1.59

Eli Lilly & Co.

Read more
19 Bristol Myers Squibb Co.
0 1 2 3 4 5
1.55

Bristol Myers Squibb Co.

Read more
0 1 2 3 4 5

The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.


Insights

  • Pfizer joins top 5

    GSK retains its number one position, yet only slightly ahead of Novartis. Pfizer moves into the top five. Johnson & Johnson and Sanofi complete the top five companies. Eight of the top ten companies, including the leaders, are setting a new best practice of systematic access planning during R&D.

    >> Ranking breakdown


  • Leaders match actions to specific needs

    Leading companies perform well across all areas of measurement, with a mature approach to managing access, addressing access to specific products. They are committed to R&D for global health priorities and specific needs of people in low- and middle- income countries. 

    >> To the report cards

  • Addressing access inches toward standard practice

    There is progress in companies integrating access to medicine into governance structures, R&D processes, and monitoring efforts. Yet initiatives addressing access to specific products remain focused on a few products and countries.

    >> Progress trends

  • 2021 Index focuses on core role for pharma

    Achieving the SDGs and UHC by 2030 means delivering health products to everyone in need. Success depends on pharma companies moving to systematically address access at all levels of the health system. The Index evaluates how companies measure up to their core role for improving access.

    >> How we measure


Get in touch

Back to top |